@nedhamson

I know that's the title of the news article you linked, and I've seen it elsewhere already, but that's not actually what they awarded money for.

"$8.5 million to CastleVax for a vector-based intranasal vaccine candidate.

$10 million to Codagenix for a live-attenuated intranasal vaccine candidate."

Out of the $500 mill that's all that's going towards nasal vaccines.

https://www.hhs.gov/about/news/2023/10/13/project-nextgen-selects-initial-vaccine-candidates-awards-over-500-million-advance-development-vaccines-therapeutics.html